Long-Term Follow-Up of Combination Therapy with Sintilimab and Anlotinib in Gallbladder Follicular Dendritic Cell Sarcoma: A Rare Case Report

References

• Gatta G, van der Zwan JM, Casali PG, et al. Rare cancers are not so rare: the rare cancer burden in Europe. Eur J Cancer. 2011;47(17):2493–2511. doi:10.1016/j.ejca.2011.08.008
   PubMed Web of Science ®Google Scholar
• Facchetti F, Simbeni M, Lorenzi L. Follicular dendritic cell sarcoma. Pathologica. 2021;113:316–329. doi:10.32074/1591-951X-331
   PubMed Web of Science ®Google Scholar
• Wang E, Zhang L, Wang Y, Zhang M. Epstein–Barr virus-negative inflammatory pseudotumor-like variant of follicular dendritic cell sarcoma of the liver: a case report. Asian J Surg. 2023;46(4):1846–1847. doi:10.1016/j.asjsur.2022.10.054
   PubMed Web of Science ®Google Scholar
• Shacklette AH, Chen S, DeWitt JM, Patel KS, Saeed OA. Fine needle aspiration cytology of follicular dendritic cell sarcoma of the stomach masquerading as gastrointestinal stromal tumor: a case report of a unique entity with emphasis on cytomorphology. Diagn Cytopathol. 2023;51(7):E214–E218. doi:10.1002/dc.25132
   PubMed Web of Science ®Google Scholar
• Lim JY, Hong SK, Huang WF. Splenic pseudotumor-like follicular dendritic cell sarcoma. J Gastrointest Surg. 2023;27(7):1486–1488. doi:10.1007/s11605-023-05630-y
   PubMed Web of Science ®Google Scholar
• Lu X, Wu Y, Gong J, Yu X, Zhang Y, Yang C. Pancreatic follicular dendritic cell sarcoma: one case report and literature review. J Int Med Res. 2022;50(12):3000605221142401. doi:10.1177/03000605221142401
   Web of Science ®Google Scholar
• Hu A, Chen T, Dong J. Promising clinical outcome after body gamma knife radiotherapy for mediastinal follicular dendritic cell sarcoma with thoracic spine invasion and iliac metastasis: a case report and literature review. Front Oncol. 2022;2022:12919644.
   Google Scholar
• Yang X, Wang D, Lin J, et al. Atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma. Lancet Oncol. 2020;21(9):e412. doi:10.1016/S1470-2045(20)30430-7
   PubMedGoogle Scholar
• Lei Y, Zhao S, Jiang M. Unexpected favorable outcome to PD-1 antibody plus lenvatinib in a patient with recurrent intestinal follicular dendritic cell sarcoma: a case report and literature review. Front Immunol. 2021;12:653319. doi:10.3389/fimmu.2021.653319
   PubMed Web of Science ®Google Scholar
• Rini BI, Plimack ER, Stus V, et al. Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. New Engl J Med. 2019;380(12):1116–1127. doi:10.1056/NEJMoa1816714
   PubMed Web of Science ®Google Scholar
• Nagtegaal ID, Odze RD, Klimstra D, et al. WHO classification of tumours editorial board. The 2019 WHO classification of tumours of the digestive system. Histopathology. 2020;76(2):182–188. doi:10.1111/his.13975
   PubMed Web of Science ®Google Scholar
• Khoury JD, Solary E, Abla O, et al. The 5th edition of the World Health Organization classification of haematolymphoid tumours: myeloid and histiocytic/dendritic neoplasms. Leukemia. 2022;36(7):1703–1719. doi:10.1038/s41375-022-01613-1
   PubMed Web of Science ®Google Scholar
• Swerdlow S, Campo E, Harris NL, et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues (Revised 4th Edition). Vol. 421. Lyon: IARC; 2017:476.
   Google Scholar
• Asiry S, Khader SN, Villanueva-Siles E, et al. Follicular dendritic cell sarcoma: cytomorphologic features and diagnostic challenges. Diagn Cytopathol. 2021;49(3):457–461. doi:10.1002/dc.24691
   PubMed Web of Science ®Google Scholar
• Sharma P, Goswami S, Raychaudhuri D, et al. Immune checkpoint therapy—current perspectives and future directions. Cell. 2023;186(8):1652–1669. doi:10.1016/j.cell.2023.03.006
   PubMed Web of Science ®Google Scholar
• Agaimy A, Michal M, Hadravsky L, Michal M. Follicular dendritic cell sarcoma: clinicopathologic study of 15 cases with emphasis on novel expression of MDM2, somatostatin receptor 2A, and PD-L1. Ann Diagn Pathol. 2016;23:21–28. doi:10.1016/j.anndiagpath.2016.05.003
   PubMed Web of Science ®Google Scholar
• Gatalica Z, Bilalovic N, Palazzo JP, et al. Disseminated histiocytoses biomarkers beyond BRAFV600E: frequent expression of PD-L1. Oncotarget. 2015;6:19819. doi:10.18632/oncotarget.4378
   PubMed Web of Science ®Google Scholar
• Lee M-Y, Bernabe-Ramirez C, Ramirez DC, Maki RG. Follicular dendritic cell sarcoma and its response to immune checkpoint inhibitors nivolumab and ipilimumab. BMJ Case Rep. 2020;13:e234363. doi:10.1136/bcr-2020-234363
   PubMedGoogle Scholar
• Li J, Ren M, Bi F, et al. Favorable response to PD-1 inhibitor plus chemotherapy as first-line treatment for metastatic follicular dendritic cell sarcoma of the spleen: a case report. Front Immunol. 2023;14:1228653. doi:10.3389/fimmu.2023.1228653
   PubMed Web of Science ®Google Scholar
• Grothey A, Van Cutsem E, Sobrero A, et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo controlled, Phase 3 trial. Lancet. 2013;381(9863):303–312. doi:10.1016/S0140-6736(12)61900-X
   PubMed Web of Science ®Google Scholar
• Bruix J, Qin S, Merle P, et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017;389(10064):56–66. doi:10.1016/S0140-6736(16)32453-9
   PubMed Web of Science ®Google Scholar
• Choueiri TK, Escudier B, Powles T, et al. Cabozantinib versus everolimus in advanced renal-cell carcinoma. New Engl J Med. 2015;373(19):1814–1823. doi:10.1056/NEJMoa1510016
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Hutson TE, Glen H, et al. Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, Phase 2, open-label, multicentre trial. Lancet Oncol. 2015;16(15):1473–1482. doi:10.1016/S1470-2045(15)00290-9
   PubMed Web of Science ®Google Scholar
• Galle PR, Finn RS, Qin S, et al. Patient-reported outcomes with atezolizumab plus bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma (IMbrave150): an open-label, randomised, phase 3 trial. Lancet Oncol. 2021;22(7):991–1001. doi:10.1016/S1470-2045(21)00151-0
   PubMed Web of Science ®Google Scholar
• Powles T, Plimack E, Soulières D, et al. Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial. Lancet Oncol. 2020;21(12):1563–1573. doi:10.1016/S1470-2045(20)30436-8
   PubMed Web of Science ®Google Scholar
• Fukumura D, Kloepper J, Amoozgar Z, Duda DG, Jain RK. Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges. Nat Rev Clin Oncol. 2018;15(5):325–340. doi:10.1038/nrclinonc.2018.29
   PubMed Web of Science ®Google Scholar
• Kudo M. Scientific rationale for combined immunotherapy with PD-1/PD-L1 antibodies and VEGF inhibitors in advanced hepatocellular carcinoma. Cancers. 2020;12(5):1089. doi:10.3390/cancers12051089
   PubMed Web of Science ®Google Scholar
• Furukawa K, Nagano T, Tachihara M, Yamamoto M, Nishimura Y. Interaction between immunotherapy and antiangiogenic therapy for cancer. Molecules. 2020;25(17):3900. doi:10.3390/molecules25173900
   PubMed Web of Science ®Google Scholar
• Hoy SM. Sintilimab: first global approval. Drugs. 2019;79(3):341–346. doi:10.1007/s40265-019-1066-z
   PubMed Web of Science ®Google Scholar
• Jin S, Zhao R, Zhou C, et al. Feasibility and tolerability of sintilimab plus anlotinib as the second-line therapy for patients with advanced biliary tract cancers: an open-label, single-arm, Phase II clinical trial. Int J Cancer. 2022;152(8):1648–1658. doi:10.1002/ijc.34372
   PubMed Web of Science ®Google Scholar
• Liu J, Gao T, Tan Z, et al. Phase II study of TQB2450, a novel PD-L1 antibody, in combination with anlotinib in patients with locally advanced or metastatic soft tissue sarcoma. Clin Cancer Res. 2022;28(16):3473–3479. doi:10.1158/1078-0432.CCR-22-1785
   PubMed Web of Science ®Google Scholar
• Zhang Y, Vu T, Palmer DC, et al. A T cell resilience model associated with response to immunotherapy in multiple tumor types. Nat Med. 2022;28(7):1421–1431. doi:10.1038/s41591-022-01799-y
   PubMed Web of Science ®Google Scholar
• Laumont CM, Banville AC, Gilardi M, Hollern DP, Nelson BH. Tumour-infiltrating B cells: immunological mechanisms, clinical impact and therapeutic opportunities. Nat Rev Cancer. 2022;22(7):414–430. doi:10.1038/s41568-022-00466-1
   PubMed Web of Science ®Google Scholar
• Dolton G, Rius C, Wall A, et al. Targeting of multiple tumor-associated antigens by individual T cell receptors during successful cancer immunotherapy. Cell. 2023;186(16):3333–3349. doi:10.1016/j.cell.2023.06.020
   PubMed Web of Science ®Google Scholar
• Tay C, Tanaka A, Sakaguchi S. Tumor-infiltrating regulatory T cells as targets of cancer immunotherapy. Cancer Cell. 2023;41(3):450–465. doi:10.1016/j.ccell.2023.02.014
   PubMed Web of Science ®Google Scholar
• Rizvi H, Sanchez-Vega F, La K, et al. Molecular determinants of response to anti-programmed cell death (PD)-1 and anti-programmed death-ligand 1 (PD-L1) blockade in patients with non-small-cell lung cancer profiled with targeted next-generation sequencing. J Clin Oncol. 2018;36(7):633–641. doi:10.1200/JCO.2017.75.3384
   PubMed Web of Science ®Google Scholar